Levofloxacin

Generic Name: Levofloxacin

Brand Names: Levaquin, Quinsair

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀FN_₃O_₄

CAS Number: 100986-85-4

Unique Ingredient Identifier: RIX4E89Y14

Background: Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication: In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions: Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria

Associated Therapies: -

Clinical Trials

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

Phase 3

Completed

Conditions: Acute Leukemias of Ambiguous Lineage
Bacterial Infection
Diarrhea
Fungal Infection
Musculoskeletal Complications
Neutropenia
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions: Drug: levofloxacin

First Posted Date: 2011-06-13

Last Posted Date: 2020-12-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 624

Registration Number: NCT01371656

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Michigan State University - Breslin Cancer Center, Lansing, Michigan, United States

and more 81 locations

Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study

Phase 4

Completed

Conditions: Disease Due to BK Polyomavirus
Kidney Transplant Infection

Interventions: Drug: Levofloxacin

First Posted Date: 2011-05-13

Last Posted Date: 2024-04-05

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 154

Registration Number: NCT01353339

Locations: 🇨🇦
Capital Health - University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
Winnipeg Health Science Center, Winnipeg, Manitoba, Canada
🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

and more 8 locations

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

Phase 3

Completed

Conditions: Pyelonephritis
Complicated Urinary Tract Infection

Interventions: Drug: CXA-201
Drug: Levofloxacin

First Posted Date: 2011-05-02

Last Posted Date: 2018-10-25

Lead Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Target Recruit Count: 558

Registration Number: NCT01345929

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Phase 2

Completed

Conditions: Community-Acquired Bacterial Pneumonia

Interventions: Drug: CEM-101
Drug: Levofloxacin

First Posted Date: 2010-07-23

Last Posted Date: 2017-03-03

Lead Sponsor: Melinta Therapeutics, Inc.

Target Recruit Count: 132

Registration Number: NCT01168713

Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

Phase 3

Completed

Conditions: Helicobacter Pylori Infection

First Posted Date: 2010-05-26

Last Posted Date: 2011-08-09

Lead Sponsor: Deva Holding A.S.

Target Recruit Count: 60

Registration Number: NCT01131026

Locations: 🇹🇷
Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology, Kayseri, Turkey

A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)

Phase 2

Completed

Conditions: Complicated Urinary Tract Infection
Acute Pyelonephritis

Interventions: Drug: plazomicin
Drug: levofloxacin
Drug: placebo

First Posted Date: 2010-03-31

Last Posted Date: 2018-08-22

Lead Sponsor: Achaogen, Inc.

Target Recruit Count: 145

Registration Number: NCT01096849

BK Treatment Study

Phase 4

Completed

Conditions: BK Viremia

Interventions: Drug: placebo
Drug: levofloxacin

First Posted Date: 2009-12-17

Last Posted Date: 2017-04-24

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 43

Registration Number: NCT01034176

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Lahey Clinic Medical Center, Burlington, Massachusetts, United States

and more 5 locations